NasdaqGM - Nasdaq Real Time Price ? USD Third Harmonic Bio, Inc. (THRD) Follow Compare 13.46 +0.35 (+2.67%) At close: October 18 at 4:00 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Third Harmonic Bio (NASDAQ:THRD) Is In A Strong Position To Grow Its Business There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Third Harmonic Bio... Simply Wall St. ? last month THRD +2.67% Third Harmonic Bio to Participate in Upcoming Investor Conferences in September SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in fireside chats at the following upcoming conferences: Stifel 2024 Virtual Immunology and Inflammation Summit on Wednesday, September 18, 2024, at 9:00 a.m. ETTD Cowen Vir GlobeNewswire ? last month THRD +2.67% Third Harmonic Bio to Participate in Upcoming Investor Conferences SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the following upcoming conferences: Morgan Stanley 22nd Healthcare Conference on Wednesday, September 4, 2024, at 9:15 a.m. ETStifel 2024 Virtual Immuno GlobeNewswire ? last month THRD +2.67% Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q’25 Strong financial position with cash and cash equivalents totaling $255.3 million as of June 30, 2024 SAN FRANCISCO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, today announced financial results for the sec GlobeNewswire ? 2 months ago THRD +2.67% Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 7:30 a.m. ET. A live audio webcast will be available within the Investors & M GlobeNewswire ? 4 months ago THRD +2.67% Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H’25 Strengthened leadership team with the appointment of Christopher J. Dinsmore, Ph.D., to Chief Scientific Officer, Dennis Dean, Ph.D., to Chief Non-Clinical Development Officer, and the promotion of Jennifer Dittman to Chief Development Operations Officer Strong financial position with cash and cash equivalents totaling $262.8 GlobeNewswire ? 5 months ago THRD +2.67% AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal AbbVie (ABBV) inks an option-to-license and collaboration deal with Gilgamesh to develop next-generation therapies for psychiatric disorders. Zacks ? 5 months ago ABBV THRD +2.67% Insider Sale: CEO Natalie Holles Sells Shares of Third Harmonic Bio Inc (THRD) Natalie Holles, Chief Executive Officer of Third Harmonic Bio Inc (NASDAQ:THRD), sold 20,222 shares of the company on May 9, 2024. GuruFocus.com ? 5 months ago THRD +2.67% Third Harmonic Bio Inc CEO Natalie Holles Sells 13,558 Shares Natalie Holles, CEO of Third Harmonic Bio Inc (NASDAQ:THRD), has sold 13,558 shares of the company on April 11, 2024, according to a recent SEC Filing. GuruFocus.com ? 6 months ago THRD +2.67% We're Not Worried About Third Harmonic Bio's (NASDAQ:THRD) Cash Burn Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... Simply Wall St. ? 6 months ago THRD +2.67% Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors. “Geoff is an outstanding addition to our board, bringing broad operational leadership and a depth of clinical and commercial experience that will benefit our work greatly as we advance our lead product candidate, THB335, i GlobeNewswire ? 6 months ago THRD +2.67% Third Harmonic Bio Inc (THRD) Reports Decreased Net Loss in Q4, Aligns with Analyst Projections THRD's Fiscal Discipline Leads to Lower Annual Net Loss Despite Zero Revenue GuruFocus.com ? 6 months ago THRD +2.67% Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results U.S. IND filed for THB335 with anticipated clinical trial start during 2Q’24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023. “Our team’s execution continue GlobeNewswire ? 6 months ago THRD +2.67% Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 1:30 p.m. ET. A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An a GlobeNewswire ? 7 months ago THRD +2.67% Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy IND-enabling toxicology studies of THB335 nearing completion; Pre-IND interaction with the U.S. FDA now complete Program remains on track to file a U.S. IND and initiate a Phase 1 study of THB335 during the first half of 2024 SAN FRANCISCO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing th GlobeNewswire ? 9 months ago THRD +2.67% Are You Looking for a Top Momentum Pick? Why Third Harmonic Bio, Inc. (THRD) is a Great Choice Does Third Harmonic Bio, Inc. (THRD) have what it takes to be a top stock pick for momentum investors? Let's find out. Zacks ? 9 months ago THRD +2.67% Insider Sell Alert: Third Harmonic Bio Inc's Julie Person Divests 12,863 Shares In the realm of biotech stocks, insider transactions are often scrutinized for hints about a company's future prospects. GuruFocus.com ? 10 months ago THRD +2.67% Third Harmonic Bio Inc (THRD) Reports Q3 2023 Financial Results and Continues Progress Towards ... Financial Position Remains Strong with Sufficient Cash Through At Least 2025 GuruFocus.com ? 11 months ago THRD +2.67% Third Harmonic Bio Announces Third Quarter 2023 Financial Results On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24 Strong financial position with cash and cash equivalents totaling $273.9 million as of September 30, 2023 SAN FRANCISCO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced financial results for the third quarter ended September 30, 2023. “We GlobeNewswire ? 11 months ago THRD +2.67% Companies Like Third Harmonic Bio (NASDAQ:THRD) Are In A Position To Invest In Growth There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... Simply Wall St. ? 11 months ago THRD +2.67% Performance Overview Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return THRD S&P 500 YTD +22.70% +22.95% 1-Year +92.56% +34.10% 3-Year -20.82% +48.62%
